Grifols (NASDAQ:GRFS) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Grifols (NASDAQ:GRFS) from a buy rating to a hold rating in a report published on Sunday.

A number of other analysts have also recently weighed in on GRFS. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Four investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Grifols currently has an average rating of “Hold” and a consensus target price of $10.00.

Grifols Stock Performance

GRFS stock opened at $8.59 on Friday. The business’s 50-day moving average is $9.18 and its two-hundred day moving average is $9.28. The company has a quick ratio of 0.88, a current ratio of 2.51 and a debt-to-equity ratio of 1.20. Grifols has a 1 year low of $6.19 and a 1 year high of $11.14.

Institutional Trading of Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in GRFS. Brandes Investment Partners LP increased its holdings in shares of Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after purchasing an additional 1,838,727 shares during the period. Capital World Investors lifted its position in Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock valued at $228,344,000 after purchasing an additional 1,273,391 shares during the period. Permian Investment Partners LP lifted its position in Grifols by 4.2% in the fourth quarter. Permian Investment Partners LP now owns 18,190,262 shares of the biotechnology company’s stock valued at $170,079,000 after purchasing an additional 737,941 shares during the period. Millennium Management LLC boosted its holdings in Grifols by 2.7% in the 4th quarter. Millennium Management LLC now owns 7,122,155 shares of the biotechnology company’s stock valued at $66,592,000 after purchasing an additional 184,874 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Grifols by 45.8% in the 4th quarter. Bank of Montreal Can now owns 4,394,750 shares of the biotechnology company’s stock valued at $41,091,000 after buying an additional 1,381,027 shares during the period.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.